VX-950 Vertex/Mitsubishi

Current Opinion in Investigational Drugs

Volumn 6, Issue 8, 2005, Pages 831-837

  Summa, Vincenzo ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CILUPREVIR; MERIMEPODIB; PEGINTERFERON; PLACEBO; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VX 950;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; DIARRHEA; DISEASE MODEL; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NAUSEA; NONHUMAN; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; URINARY FREQUENCY; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; HUMANS; OLIGOPEPTIDES; PATENTS; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 23344440213     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. 250154 Vertex and Eli Lilly form strategic alliance to develop drugs to treat hepatitis C infection. Vertex Pharmaceuticals Inc PRESS RELEASE 1997 June 13
2. 356013 Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM J VIROL 2000 74 4 2046-2051
3. 435040 Lilly and Vertex select HCV candidate for development. Eli Lilly & Co PRESS RELEASE 2002 January 07
4. 475316 Vertex to lead VX-950 development, amends Lilly agreement. Vertex Pharmaceuticals Inc PRESS RELEASE 2003 January 02
5. 502281 Solid phase parallel synthesis of α-ketoamide inhibitors of NS3.4A HCV protease. Court JJ, Cottrell KC, Harbeson SL, Pitlik J ACS 2003 226 Abs MEDI 97
6. 502282 Hepatitis C NS3-4A protease inhibitors: Design of reversible covalent warhead. Perni RB, Britt SD, Court JJ, Courtney LF, Deininger DD, Farmer LJ, Gates CA, Harberson SL, Kim JL, Levin R, Moon Y-C et al ACS 2003 226 Abs MEDI 98
7. 502283 Hepatitis C NS3-4A protease inhibitors: Extensive structure-activity relationship exploration of potent, covalent ketoamide based inhibitors. Pitlik J, Britt SD, Cottrell KC, Court JJ, Courtney LF, Deininger DD, Gates CA, Lin C, Lin K, Luong Y-P, Perni RB et al ACS 2003 226 Abs MEDI 99
8. 502284 Ketoamide-based inhibitors of the HCV NS3-NS4A protease: P3 truncation studies. Pitlik J, Britt SD, Cottrell KC, Court JJ, Courtney LF, Gates CA, Harbeson SL, Luong Y-P, Perni RB, Rao BG, Thomson JA et al ACS 2003 226 Abs MEDI 100
9. 510538 Vertex's HCV protease inhibitor VX-950 shows preclinical promise. Vertex Pharmaceuticals Inc PRESS RELEASE 2003 October 27
10. 511533 National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). GASTROENTEROLOGY 2002 123 6 2082-2099
11. 513647 Future Antivirals - SMi Conference. Latest developments in HIV, Hepatitis, Herpes, Influenza, RSV and SARS, London, UK. Harrison R IDDB MEETING REPORT 2003 November 12-13
12. 514086 The American Association for the Study of Liver Diseases - 54th Annual Meeting, Boston, MA, USA, 24-28 October 2003. Susman E IDDB MEETING REPORT 2003
13. 533196 Vertex Pharmaceuticals reports data on investigational hepatitis C therapies suggesting potential for novel treatment approaches. Vertex Pharmaceuticals Inc PRESS RELEASE 2004 April 16
14. 533720 Protease Inhibitors - ScreenTech World Summit, San Diego, CA, USA, 23-24 March 2004. Stewart K IDDB MEETING REPORT 2004 March 23-24
15. 535818 Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants. Perni RB, Britt SD, Court JJ, Courtney LF, Deininger DD, Farmer LJ, Gates CA, Harbeson SL, Kim JL, Landro JA, Levin RB et al BIOORG MED CHEM LETT 2003 13 22 4059-4063
16. 536309 Vertex combines pipeline candidates in HCV studies. Vertex Pharmaceuticals Inc PRESS RELEASE 2004 May 04
17. 540281 International Society for Antiviral Research - 17th Annual International Conference on Antiviral Research (Part II), Tucson, AZ, USA, 2-6 May 2004. Smee D IDDB MEETING REPORT 2004 02-06 May
18. 542937 Vertex's oral protease inhibitor enters the clinic for HCV. Vertex Pharmaceuticals Inc PRESS RELEASE 2004 June 08
19. 542949 In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: Structural analysis indicates different resistance mechanisms. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM et al J BIOL CHEM 2004 279 17 17508-17514
20. 544354 Vertex outlicenses Asian rights to oral HCV drug. Vertex Pharmaceuticals Inc PRESS RELEASE 2004 June 14
21. 547667 Hepatitis C. Thomas DL, Lemon SM. In: MANDELL, DOUGLAS, AND BENNETT'S PRINCIPLES AND PRACTICE OF INFECTIOUS DISEASES, Mandell GL, Bennett JE, Dolin R, (Eds) Churchill Livingston, Philadelphia, PA, USA 2000 6 1736-1760
22. 550035 Progress and development of small molecule HCV antivirals. Ni Z-J, Wagman AS CURR OPIN DRUG DISCOVERY DEV 2004 7 4 446-459
23. 557798 Vertex Pharmaceuticals reports completion of dosing in the phase Ia clinical study of VX-950, an oral HCV protease inhibitor for the treatment of hepatitis C. Vertex Pharmaceuticals Inc PRESS RELEASE 2004 September 07
24. 560160 Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants. Perni RB, Farmer LJ, Cottrell KM, Court JJ, Courtney LF, Deininger DD, Gates CA, Harbeson SL, Kim JL, Lin C, Lin K et al BIOORG MED CHEM LETT 2004 14 8 1939-1942
25. 567855 Vertex Pharmaceuticals reports positive results from first-in-human study for VX-950, an investigational oral protease inhibitor for the treatment of hepatitis C. Vertex Pharmaceuticals Inc PRESS RELEASE 2004 November 01
26. 569516 Vertex Pharmaceuticals announces advancement to phase Ib clinical trial for VX-950, an investigational oral protease inhibitor for the treatment of hepatitis C. Vertex Pharmaceuticals Inc PRESS RELEASE 2004 November 08
27. 571269 Comparison of two anti-HCV clinical candidates, VX-950 and BILN 2061, for potency and resistance in the HCV replicon system and in a novel HCV protease animal model. Lin K, Lin C, Kalkeri G, Almquist S, Luong YP, Rao BG, Wei Y, Gates CA, Perni RB, Kwong AD ANTIVIR RES 2004 62 2 A83-A84
28. 571270 In vitro combination studies of VX-950 (a HCV protease inhibitor) or VX-497 (an IMPDH inhibitor), two novel anti-HCV clinical candidates, with IFN-α. Lin K, Lin C, Kwong AD ANTIVIR RES 2004 62 2 A52
29. 571271 VX-950, a novel HCV protease inhibitor, retains potency against BILN-2061 resistant replicon cells: Computational analysis indicates that resistance develops via different mechanisms. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan D, Fulghum J Frantz D, Hsiao HM, Ma S, Maxwell J et al J HEPATOL 2004 40 Suppl 1 21
30. 571272 Clearance and rebound kinetics of HCV RNA in replicon cells treated with VX-950, a novel HCV NS34A protease inhibitor, alone or in combination with interferon-α. Lin K, Perni RB, Kwong AD, Lin C J HEPATOL 2004 40 Suppl 1 11
31. 571273 VX-950: The discovery of an inhibitor of the hepatitis C NS3.4A protease and a potential hepatitis C virus therapeutic. Perni RB, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Gates CA, Harbeson SL, Kwong AD, Lin C, Luong YP, Markland W et al HEPATOLOGY 2003 38 4 Abs 972
32. 574833 Mechanism-based design of synergistic therapeutics for hepatitis C. Thomson J SMI CONF - ADV ANTIVIR THER 2004 December 01-02
33. 590948 Hepatitis C treatment update. Pearlman BL AM J MED 2004 117 5 344-352
34. 600335 Vertex Pharmaceuticals reports that VX-950, an investigational oral hepatitis C protease inhibitor, displays potent antiviral activity in early clinical study. Vertex Pharmaceuticals Inc PRESS RELEASE 2005 May 10
35. 601958 Vertex Pharmaceuticals reports that oral hepatitis C protease inhibitor, VX-950, dramatically reduces viral levels in phase Ib clinical study. Vertex Pharmaceuticals Inc PRESS RELEASE 2005 May 17
36. 604401 P4 and P1′ optimization of bicycloproline P2 bearing tetrapeptidyl α-ketoamides as HCV protease inhibitors. Yip Y, Victor F, Lamar J, Johnson R, Wang QM, Glass JI, Yumibe N, Wakulchik M, Munroe J, Chen SH BIOORG MED CHEM LETT 2004 14 19 5007-5011
37. 605083 Liver transplantation and hepatitis C. Willems M, Metselaar HJ, Tilanus HW, Schalm SW, de Man RA TRANSPLANT INT 2002 15 2-3 61-72
38. 605086 Side effects of therapy of hepatitis C and their management. Fried MW HEPATOLOGY 2002 36 5 Suppl 1 S237-S244
39. 605507 Combination of a hepatitis C virus NS3-NS4A protease inhibitor and α interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Lin K, Kwong AD, Lin C ANTIMICROB AGENTS CHEMOTHER 2004 48 12 4784-4792
40. 605665 P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl α-ketoamide based HCV protease inhibitors. Victor F, Lamar J, Snyder N, Yip Y, Guo D, Yumibe N, Johnson RB, Wang QM, Glass JI, Chen SH BIOORG MED CHEM LETT 2004 14 1 257-261
41. 606028 Treatment of chronic hepatitis C: A systematic review. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, Gebo KA HEPATOLOGY 2002 36 5 Suppl 1 S135-S144
42. 606762 P1 and P1′ optimization of [3,4]-bicycloproline P2 incorporated tetrapeptidyl α-ketoamide based HCV protease inhibitors. Chen S, Lamar J, Yip Y, Victor F, Johnson RB, Wang QM, Glass JI, Heinz B, Colacino J, Guo D, Tebbe M, Munroe JE LETT DRUG DES DISCOVERY 2005 2 2 118-123
43. 606773 Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Reiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wederneyer H, Avendano C, Riba N, Yong CL, Nehmiz G, Steinmann GG HEPATOLOGY 2005 41 4 832-835
44. 606825 Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M SCIENCE 2005 244 4902 359-362
45. 607083 Initial results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Reesink HW, Zeuzem S, Van Vliet A, McNair L, Purdy S, Chu HM, Jansen PLM GASTROENTEROLOGY 2005 28 4 Suppl 2 Abs 527
46. 610888 Vertex initiates phase 2 VX-702 RA study. Troyer R, Augustine M, Park M CREDIT SUISSE FIRST BOSTON 2005 June 10
47. 611232 Bear-Biotech-Confab Update. Schoenebaum M, Samad A BEAR STEARNS CO INC 2005 June 28